RANI - NASDAQ

Rani Therapeutics Holdings, Inc.

RANI·NASDAQ

$0.92

+7.9%

HealthcareBiotechnology

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$59.90M

EPS-0.4500

P/E Ratio-2.04

Earnings Date08/06/2026

rani

Other Non-Cash Items

Last Annual Value

-8.70M

3-Year CAGR

-855%

5-Year CAGR

-140%

10-Year CAGR

-60%

Adjust for Inflation

Rani Therapeutics Holdings, Inc. Competitors Analysis of Other Non-Cash Items

RANI · NASDAQ

Company	Other Non-Cash Items	CAGR 3Y	CAGR 5Y	CAGR 10Y
Rani Therapeutics Holdings, Inc. NASDAQ:RANI	-8.70M	N/A	N/A	N/A
Corbus Pharmaceuticals Holdings, Inc. NASDAQ:CRBP	-229.00K	N/A	N/A	N/A
Elicio Therapeutics, Inc. NASDAQ:ELTX	2.24M	120.4%	27.4%	N/A
Tonix Pharmaceuticals Holding Corp. NASDAQ:TNXP	5.85M	73.3%	14.3%	46.0%
Annovis Bio, Inc. NYSE:ANVS	1.44B	394.9%	N/A	N/A
AN2 Therapeutics, Inc. NASDAQ:ANTX	-1.07M	N/A	N/A	N/A
Verrica Pharmaceuticals Inc. NASDAQ:VRCA	2.76M	-6.2%	13.9%	N/A
X4 Pharmaceuticals, Inc. NASDAQ:XFOR	-9.42M	N/A	N/A	N/A
Applied Therapeutics, Inc. NASDAQ:APLT	4.91M	-56.2%	N/A	N/A
Cardiff Oncology, Inc. NASDAQ:CRDF	-848.00K	N/A	N/A	N/A
Sangamo Therapeutics, Inc. NASDAQ:SGMO	13.27M	-55.8%	N/A	45.1%

Rani Therapeutics Holdings, Inc. Fair Value Envelope

RANI · NASDAQ

Our analysis suggests that RANI has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $0.917, this represents a potential HIDDEN relative to our calculated worth for Rani Therapeutics Holdings, Inc..

HIDDEN

Intrinsic Value

Current Price: $0.917

Related Guides

Blog Categories

Continue your RANI research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.